Shares of Abeona Therapeutics Inc. (ABEO) were in the spotlight on Tuesday afternoon after it announced that the U.S. Food ...

Persistence has paid off for Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

Researchers at the University Health Network (UHN) and the University of Toronto have developed a skin-based test that can ...

Both gene therapies were approved as treatments for dystrophic epidermolysis bullosa, a rare and debilitating genetic skin condition.

Cleveland-based Abeona Therapeutics Inc. (Nasdaq: ABEO) announced Tuesday, April 29, that it has received U.S. Food and Drug ...

Matter of Time,” a documentary featuring legendary rocker Eddie Vedder premiering this fall at the Tribeca Film Festival, is ...

The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was ...

rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the United States Patent and Trademark Office (USPTO) issued ...

The global burden of chronic kidney disease (CKD) is rising, with more than 800 million people affected worldwide. Vascular diseases in patients with CKD are unique and grouped as uremic vascular ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...

The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.